OnKure Therapeutics, Inc. — Director's Dealing 2021

Apr 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Reneo Pharmaceuticals, Inc. (RPHM)
CIK: 0001637715
Period of Report: 2021-04-13

Reporting Person: Novo Holdings A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-13	COMMON STOCK	C	2763711	—	Acquired	2763711	Direct
2021-04-13	COMMON STOCK	P	666666	$15.00	Acquired	3430377	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-13	SERIES B CONVERTIBLE PREFERRED STOCK	$	C	12367054	Disposed		COMMON STOCK (2763711)	Direct

Footnotes

F1: Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.

F2: Represents a purchase from the underwriters in the Issuer's initial public offering.